The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

October 10, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“There are many similarities between these conditions, and one could think that they belong not only to the same family but possibly to the same syndrome,” he said.

You Might Also Like
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
Explore This Issue
October 2016
Also By This Author
  • ACR Leaders Discuss E/M Coding Changes, Step Therapy & More

A recent study attempted to pinpoint differences between large-vessel GCA (LV-GCA) and classic GCA (C-GCA). Researchers found that those with LV-GCA tended to be younger, with a longer period of symptoms before being diagnosed and more commonly had a history of polymyalgia rheumatica, but a smaller number of them had cranial symptoms. Patients with LV-GCA had a lower rate of blindness but a higher relapse rate and greater steroid doses, researchers found.6

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

New large-vessel vasculitis biomarkers, which could help with identification and management of the disease, have emerged over the past few years, including pentraxin-3, which has shown high specificity compared to controls and has even shown some ability to differentiate between active disease and disease in remission.7

Promising data have also been generated on antiferritin antibodies and antibodies to the 14-3-3 aorta protein, the newest biomarker candidate, which has been seen frequently in patients with different types of LVV and not often seen in controls, Dr. Cimmino said.8,9

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

But these biomarkers, he said, “should be studied in the long term to evaluate their prognostic [value].”


Thomas R. Collins is a freelance medical writer based in Florida.

References

  1. Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: A cohort study. Arthritis Care Res (Hoboken). 2012 Apr;64(4):581–588.
  2. Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015 Nov 3;132(18):1693–700.
  3. Goel R, Danda D, Kumar S, et al. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis. 2013 Dec;16(6):754–761.
  4. Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016 May 7;387(10031):1921–1927.
  5. Langford C, Cuthbertson D, Ytterberg S, et al. A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis. Abstract 9L. Presented Nov. 10, 2015. American College of Rheumatology Annual Meeting. San Francisco.
  6. Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: A cohort study. Rheumatology (Oxford). 2015 Mar;54(3):463–470.
  7. Ishihara T, Haraguchi G, Kamiishi T, et al. Sensitive assessment of activity of Takayasu’s arteritis by pentraxin3, a new biomarker. J Am Coll Cardiol. 2011 Apr 19;57(16):1712–1713.
  8. Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis. 2012 Jun;71(6):943–947.
  9. Chakravarti R, Gupta K, Swain M, et al. 14-3-3 in thoracic aortic aneurysms: Identification of a novel autoantigen in large vessel vasculitis. Arthritis Rheumatol. 2015 Jul;67(7):1913–1921.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, Vasculitis Tagged With: biologic therapies, Giant Cell Arteritis, Glucocorticoids, Research, Takayasu’s Arteritis, therapy, Treatment, VasculitisIssue: October 2016

You Might Also Like:
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • Large Vessel Vasculitis Outcome Measures: An Update from OMERACT
  • Large-Vessel Involvement Is an Independent Risk Factor Predicting GCA Mortality

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)